...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cellular physiology. >Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?
【24h】

Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?

机译：针对宫颈癌:有作用保利(ADP-ribose)聚合酶抑制?

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Patients with metastatic and recurrent cervical cancer (CC) have a poor prognosis with limited palliative treatment options. Increasing understanding of the cellular aberrations inherent to cancer cells has allowed the development of therapies to target biological pathways, an important step toward the individualization of cancer therapy. The poly (ADP-ribose) polymerase (PARP) family of enzymes is important in several DNA repair pathways. Drugs that inhibit these PARP enzymes have been investigated in many types of cancer and their application in the treatment of gynecologic malignancies has rapidly evolved. Although the majority of data for PARPi in gynecologic malignancies has been specifically regarding ovarian cancer, their role in the treatment of uterine and CC is currently being investigated. This review will examine PARP inhibitors in CC, summarizes the critical clinical trials of PARP inhibitors that have been completed, provides an overview of the on-going trials, presents the confirmed conclusions and notes the issues that need to be addressed in future studies.
机译：转移和复发性宫颈癌患者癌症(CC)有一个有限的不良预后姑息治疗方案。对细胞畸变的理解固有的癌细胞已经允许目标生物疗法的发展途径,一个重要的一步个性化的癌症疗法。(ADP-ribose)聚合酶(PARP)家族的酶在几个DNA修复途径是很重要的。这些药物抑制PARP酶在很多类型的癌症和调查在治疗妇科中的应用恶性肿瘤已迅速发展。大多数数据PARPi妇科恶性肿瘤已经特别有关治疗卵巢癌,他们的作用子宫和CC目前正在调查中。本文将研究在CC PARP抑制剂,总结了PARP的关键的临床试验抑制剂已经完成,提供了一个正在进行的试验的概述,介绍了证实了结论和笔记的问题需要在将来的研究中得到解决。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号